Identification and Functional Characterization of Glycosylation of Recombinant Human Platelet-Derived Growth Factor-BB in Pichia pastoris

Yeast Pichia pastoris is a widely used system for heterologous protein expression. However, post-translational modifications, especially glycosylation, usually impede pharmaceutical application of recombinant proteins because of unexpected alterations in protein structure and function. The aim of this study was to identify glycosylation sites on recombinant human platelet-derived growth factor-BB (rhPDGF-BB) secreted by P. pastoris, and investigate possible effects of O-linked glycans on PDGF-BB functional activity. PDGF-BB secreted by P. pastoris is very heterogeneous and contains multiple isoforms. We demonstrated that PDGF-BB was O-glycosylated during the secretion process and detected putative O-glycosylation sites using glycosylation staining and immunoblotting. By site-directed mutagenesis and high-resolution LC/MS analysis, we, for the first time, identified two threonine residues at the C-terminus as the major O-glycosylation sites on rhPDGF-BB produced in P. pastoris. Although O-glycosylation resulted in heterogeneous protein expression, the removal of glycosylation sites did not affect rhPDGF-BB mitogenic activity. In addition, the unglycosylated PDGF-BBΔGly mutant exhibited the immunogenicity comparable to that of the wild-type form. Furthermore, antiserum against PDGF-BBΔGly also recognized glycosylated PDGF-BB, indicating that protein immunogenicity was unaltered by glycosylation. These findings elucidate the effect of glycosylation on PDGF-BB structure and biological activity, and can potentially contribute to the design and production of homogeneously expressed unglycosylated or human-type glycosylated PDGF-BB in P. pastoris for pharmaceutical applications.

[1]  R. Strasser,et al.  Using glyco-engineering to produce therapeutic proteins , 2015, Expert opinion on biological therapy.

[2]  P. Robbins,et al.  Effects of N-glycan precursor length diversity on quality control of protein folding and on protein glycosylation. , 2015, Seminars in cell & developmental biology.

[3]  S. Hamilton,et al.  A practical approach for O-linked mannose removal: the use of recombinant lysosomal mannosidase , 2015, Applied Microbiology and Biotechnology.

[4]  N. Callewaert,et al.  Engineering yeast for producing human glycoproteins: where are we now? , 2015, Future microbiology.

[5]  Essi V. Koskela,et al.  Glycoengineering of yeasts from the perspective of glycosylation efficiency. , 2014, New biotechnology.

[6]  Mariana Henriques,et al.  Glycosylation: impact, control and improvement during therapeutic protein production , 2014, Critical reviews in biotechnology.

[7]  Gary Walsh,et al.  Biopharmaceutical benchmarks 2014 , 2014, Nature Biotechnology.

[8]  E. Reuven,et al.  Glycans in immune recognition and response. , 2014, Carbohydrate research.

[9]  H. Schwab,et al.  Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production , 2014, Applied Microbiology and Biotechnology.

[10]  S. Hamilton,et al.  In vitro enzymatic treatment to remove O-linked mannose from intact glycoproteins , 2014, Applied Microbiology and Biotechnology.

[11]  Anton Glieder,et al.  New opportunities by synthetic biology for biopharmaceutical production in Pichia pastoris , 2013, Current opinion in biotechnology.

[12]  A. Glieder,et al.  Knockout of an endogenous mannosyltransferase increases the homogeneity of glycoproteins produced in Pichia pastoris , 2013, Scientific Reports.

[13]  W. Cook,et al.  Production of sialylated O-linked glycans in Pichia pastoris. , 2013, Glycobiology.

[14]  L. Wells,et al.  O-Mannosylation and human disease , 2013, Cellular and Molecular Life Sciences.

[15]  Ming-Tang Chen,et al.  Characterization of the Pichia pastoris Protein-O-mannosyltransferase Gene Family , 2013, PloS one.

[16]  S. Hamilton,et al.  Binding of DC-SIGN to glycoproteins expressed in glycoengineered Pichia pastoris. , 2012, Journal of immunological methods.

[17]  U. Rova,et al.  Mannosylated Mucin-Type Immunoglobulin Fusion Proteins Enhance Antigen-Specific Antibody and T Lymphocyte Responses , 2012, PloS one.

[18]  André M Deelder,et al.  Protein O-glycosylation analysis , 2012, Biological chemistry.

[19]  R. Jordan,et al.  U-2012: An improved Lowry protein assay, insensitive to sample color, offering reagent stability and enhanced sensitivity. , 2012, BioTechniques.

[20]  Lance Wells,et al.  Mammalian O-mannosylation: unsolved questions of structure/function. , 2011, Current opinion in structural biology.

[21]  R. Neutze,et al.  Glycosylation Increases the Thermostability of Human Aquaporin 10 Protein* , 2011, The Journal of Biological Chemistry.

[22]  V. Panin,et al.  Protein O-mannosylation in animal development and physiology: from human disorders to Drosophila phenotypes. , 2010, Seminars in cell & developmental biology.

[23]  Hyun Joo An,et al.  Determination of glycosylation sites and site-specific heterogeneity in glycoproteins. , 2009, Current opinion in chemical biology.

[24]  S. Strahl,et al.  Protein O-mannosylation: conserved from bacteria to humans. , 2009, Glycobiology.

[25]  Yves Van de Peer,et al.  Genome sequence of the recombinant protein production host Pichia pastoris , 2009, Nature Biotechnology.

[26]  S. Levitz,et al.  Effect of Differential N-linked and O-linked Mannosylation on Recognition of Fungal Antigens by Dendritic Cells , 2007, PloS one.

[27]  S. Levitz,et al.  Effects of fungal N- and O-linked mannosylation on the immunogenicity of model vaccines. , 2007, Vaccine.

[28]  Guangxing Li,et al.  Select what you need: a comparative evaluation of the advantages and limitations of frequently used expression systems for foreign genes. , 2007, Journal of biotechnology.

[29]  R. Spiro Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. , 2002, Glycobiology.

[30]  M. Nagai,et al.  Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers , 2002, Expert opinion on biological therapy.

[31]  U. Vitt,et al.  Evolution and classification of cystine knot-containing hormones and related extracellular signaling molecules. , 2001, Molecular endocrinology.

[32]  M. Berridge,et al.  Superoxide produced by activated neutrophils efficiently reduces the tetrazolium salt, WST-1 to produce a soluble formazan: a simple colorimetric assay for measuring respiratory burst activation and for screening anti-inflammatory agents. , 2000, Journal of immunological methods.

[33]  W. Kenney,et al.  Disulfide bonds in recombinant human platelet-derived growth factor BB dimer: characterization of intermolecular and intramolecular disulfide linkages. , 1993, Biochemistry.

[34]  A. H. Drummond,et al.  Two PDGF‐B chain residues, arginine 27 and isoleucine 30, mediate receptor binding and activation. , 1991, The EMBO journal.

[35]  N Jentoft,et al.  Why are proteins O-glycosylated? , 1990, Trends in biochemical sciences.

[36]  C. Batt,et al.  Protein secretion in Pichia pastoris and advances in protein production , 2011, Applied Microbiology and Biotechnology.

[37]  Roland Contreras,et al.  Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology , 2008, Nature Protocols.

[38]  R. Diegelmann,et al.  Wound healing: an overview of acute, fibrotic and delayed healing. , 2004, Frontiers in bioscience : a journal and virtual library.

[39]  Gary Walsh,et al.  Biopharmaceutical benchmarks , 2000, Nature Biotechnology.